XPhyto Therapeutics (CSE: XPHY-OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive to provide a look at their German subsidiary, Vektor Pharma who is currently advancing two sublingual ODF development programs for the delivery of the active pharmaceutical ingredients.
Rogers telling Proactive the program is on track and a European human study for its sublingual CBD product is planned for Q1 2021 with results expected in Q2 2021.
Price: 1.95 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Director Interviews
XPhyto Therapeutics Corp (CSE:XPHY) (OTCQB:XPHYF) (FRA:4XT) CEO Hugh Rogers tells Proactive the group's German subsidiary Vektor Pharma TF GmbH has developed an oral disintegrating film (ODF) drug delivery mechanism for a major European generic drug company. Rogers says during the third...
Retail & consumer
Retail & consumer
Prev article
